Outcome of autologous transplantation for mantle cell lymphoma: A study by the European Blood and Bone Marrow Transplant and Autologous Blood and Marrow Transplant Registries

Elisabeth Vandenberghe, Carmen Ruiz De Elvira, Fausto R. Loberiza, E. Conde, A. López-Guillermo, C. Gisselbrecht, F. Guilhot, Julie Marie Vose, Koen Van Biesen, J. Douglas Rizzo, Dennis D. Weisenburger, Peter Isaacson, Mary M. Horowitz, Anthony H. Goldstone, Hillard M. Lazarus, Norbert Schmitz

Research output: Contribution to journalArticle

138 Citations (Scopus)

Abstract

Mantle cell lymphoma (MCL) has an aggressive clinical course with a median survival < 3 years and is incurable with conventional chemotherapy. A large multi-centre study with adequate follow-up may clarify the role of significant factors affecting outcome in autologous stem cell transplantation for MCL. Patients receiving an autologous transplant for MCL between 1988 and 1998, and reported to the European Blood and bone Marrow Transplant (EBMT) registry or Autologous Blood and Marrow Transplant Registry (ABMTR), were included. Expert haematopathology review was required on all identified patients. Disease and transplant details were requested from the transplant centres, and the final cohort of patients with verified pathology, adequate clinical information and follow-up was analysed. One hundred and ninety-five patients were included in the analyses (149 EBMT, 46 ABMTR) with a median follow-up of 3.9 years. The 2 year and 5 year overall survival were 76% and 50%, and progression free survival was 55% and 33% respectively. Disease status at transplant was the most significant factor affecting survival: patients with chemosensitive disease but not in first complete remission (CR1) were 2.99 times (95% CI: 1.66-5.38, P < 0.001) more likely to die than patients transplanted in CR1. Autologous transplantation probably improves survival in patients with MCL especially if performed in first CR.

Original languageEnglish (US)
Pages (from-to)793-800
Number of pages8
JournalBritish Journal of Haematology
Volume120
Issue number5
DOIs
StatePublished - Mar 1 2003

Fingerprint

Mantle-Cell Lymphoma
Autologous Transplantation
Autografts
Registries
Bone Marrow
Transplants
Survival
Clinical Pathology
Stem Cell Transplantation
Disease-Free Survival
Drug Therapy

Keywords

  • Autologous transplantation
  • Mantle cell lymphoma

ASJC Scopus subject areas

  • Hematology

Cite this

Outcome of autologous transplantation for mantle cell lymphoma : A study by the European Blood and Bone Marrow Transplant and Autologous Blood and Marrow Transplant Registries. / Vandenberghe, Elisabeth; Ruiz De Elvira, Carmen; Loberiza, Fausto R.; Conde, E.; López-Guillermo, A.; Gisselbrecht, C.; Guilhot, F.; Vose, Julie Marie; Van Biesen, Koen; Rizzo, J. Douglas; Weisenburger, Dennis D.; Isaacson, Peter; Horowitz, Mary M.; Goldstone, Anthony H.; Lazarus, Hillard M.; Schmitz, Norbert.

In: British Journal of Haematology, Vol. 120, No. 5, 01.03.2003, p. 793-800.

Research output: Contribution to journalArticle

Vandenberghe, E, Ruiz De Elvira, C, Loberiza, FR, Conde, E, López-Guillermo, A, Gisselbrecht, C, Guilhot, F, Vose, JM, Van Biesen, K, Rizzo, JD, Weisenburger, DD, Isaacson, P, Horowitz, MM, Goldstone, AH, Lazarus, HM & Schmitz, N 2003, 'Outcome of autologous transplantation for mantle cell lymphoma: A study by the European Blood and Bone Marrow Transplant and Autologous Blood and Marrow Transplant Registries', British Journal of Haematology, vol. 120, no. 5, pp. 793-800. https://doi.org/10.1046/j.1365-2141.2003.04140.x
Vandenberghe, Elisabeth ; Ruiz De Elvira, Carmen ; Loberiza, Fausto R. ; Conde, E. ; López-Guillermo, A. ; Gisselbrecht, C. ; Guilhot, F. ; Vose, Julie Marie ; Van Biesen, Koen ; Rizzo, J. Douglas ; Weisenburger, Dennis D. ; Isaacson, Peter ; Horowitz, Mary M. ; Goldstone, Anthony H. ; Lazarus, Hillard M. ; Schmitz, Norbert. / Outcome of autologous transplantation for mantle cell lymphoma : A study by the European Blood and Bone Marrow Transplant and Autologous Blood and Marrow Transplant Registries. In: British Journal of Haematology. 2003 ; Vol. 120, No. 5. pp. 793-800.
@article{39ad580f49e440f0a69cb16984013a12,
title = "Outcome of autologous transplantation for mantle cell lymphoma: A study by the European Blood and Bone Marrow Transplant and Autologous Blood and Marrow Transplant Registries",
abstract = "Mantle cell lymphoma (MCL) has an aggressive clinical course with a median survival < 3 years and is incurable with conventional chemotherapy. A large multi-centre study with adequate follow-up may clarify the role of significant factors affecting outcome in autologous stem cell transplantation for MCL. Patients receiving an autologous transplant for MCL between 1988 and 1998, and reported to the European Blood and bone Marrow Transplant (EBMT) registry or Autologous Blood and Marrow Transplant Registry (ABMTR), were included. Expert haematopathology review was required on all identified patients. Disease and transplant details were requested from the transplant centres, and the final cohort of patients with verified pathology, adequate clinical information and follow-up was analysed. One hundred and ninety-five patients were included in the analyses (149 EBMT, 46 ABMTR) with a median follow-up of 3.9 years. The 2 year and 5 year overall survival were 76{\%} and 50{\%}, and progression free survival was 55{\%} and 33{\%} respectively. Disease status at transplant was the most significant factor affecting survival: patients with chemosensitive disease but not in first complete remission (CR1) were 2.99 times (95{\%} CI: 1.66-5.38, P < 0.001) more likely to die than patients transplanted in CR1. Autologous transplantation probably improves survival in patients with MCL especially if performed in first CR.",
keywords = "Autologous transplantation, Mantle cell lymphoma",
author = "Elisabeth Vandenberghe and {Ruiz De Elvira}, Carmen and Loberiza, {Fausto R.} and E. Conde and A. L{\'o}pez-Guillermo and C. Gisselbrecht and F. Guilhot and Vose, {Julie Marie} and {Van Biesen}, Koen and Rizzo, {J. Douglas} and Weisenburger, {Dennis D.} and Peter Isaacson and Horowitz, {Mary M.} and Goldstone, {Anthony H.} and Lazarus, {Hillard M.} and Norbert Schmitz",
year = "2003",
month = "3",
day = "1",
doi = "10.1046/j.1365-2141.2003.04140.x",
language = "English (US)",
volume = "120",
pages = "793--800",
journal = "British Journal of Haematology",
issn = "0007-1048",
publisher = "Wiley-Blackwell",
number = "5",

}

TY - JOUR

T1 - Outcome of autologous transplantation for mantle cell lymphoma

T2 - A study by the European Blood and Bone Marrow Transplant and Autologous Blood and Marrow Transplant Registries

AU - Vandenberghe, Elisabeth

AU - Ruiz De Elvira, Carmen

AU - Loberiza, Fausto R.

AU - Conde, E.

AU - López-Guillermo, A.

AU - Gisselbrecht, C.

AU - Guilhot, F.

AU - Vose, Julie Marie

AU - Van Biesen, Koen

AU - Rizzo, J. Douglas

AU - Weisenburger, Dennis D.

AU - Isaacson, Peter

AU - Horowitz, Mary M.

AU - Goldstone, Anthony H.

AU - Lazarus, Hillard M.

AU - Schmitz, Norbert

PY - 2003/3/1

Y1 - 2003/3/1

N2 - Mantle cell lymphoma (MCL) has an aggressive clinical course with a median survival < 3 years and is incurable with conventional chemotherapy. A large multi-centre study with adequate follow-up may clarify the role of significant factors affecting outcome in autologous stem cell transplantation for MCL. Patients receiving an autologous transplant for MCL between 1988 and 1998, and reported to the European Blood and bone Marrow Transplant (EBMT) registry or Autologous Blood and Marrow Transplant Registry (ABMTR), were included. Expert haematopathology review was required on all identified patients. Disease and transplant details were requested from the transplant centres, and the final cohort of patients with verified pathology, adequate clinical information and follow-up was analysed. One hundred and ninety-five patients were included in the analyses (149 EBMT, 46 ABMTR) with a median follow-up of 3.9 years. The 2 year and 5 year overall survival were 76% and 50%, and progression free survival was 55% and 33% respectively. Disease status at transplant was the most significant factor affecting survival: patients with chemosensitive disease but not in first complete remission (CR1) were 2.99 times (95% CI: 1.66-5.38, P < 0.001) more likely to die than patients transplanted in CR1. Autologous transplantation probably improves survival in patients with MCL especially if performed in first CR.

AB - Mantle cell lymphoma (MCL) has an aggressive clinical course with a median survival < 3 years and is incurable with conventional chemotherapy. A large multi-centre study with adequate follow-up may clarify the role of significant factors affecting outcome in autologous stem cell transplantation for MCL. Patients receiving an autologous transplant for MCL between 1988 and 1998, and reported to the European Blood and bone Marrow Transplant (EBMT) registry or Autologous Blood and Marrow Transplant Registry (ABMTR), were included. Expert haematopathology review was required on all identified patients. Disease and transplant details were requested from the transplant centres, and the final cohort of patients with verified pathology, adequate clinical information and follow-up was analysed. One hundred and ninety-five patients were included in the analyses (149 EBMT, 46 ABMTR) with a median follow-up of 3.9 years. The 2 year and 5 year overall survival were 76% and 50%, and progression free survival was 55% and 33% respectively. Disease status at transplant was the most significant factor affecting survival: patients with chemosensitive disease but not in first complete remission (CR1) were 2.99 times (95% CI: 1.66-5.38, P < 0.001) more likely to die than patients transplanted in CR1. Autologous transplantation probably improves survival in patients with MCL especially if performed in first CR.

KW - Autologous transplantation

KW - Mantle cell lymphoma

UR - http://www.scopus.com/inward/record.url?scp=0037336639&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037336639&partnerID=8YFLogxK

U2 - 10.1046/j.1365-2141.2003.04140.x

DO - 10.1046/j.1365-2141.2003.04140.x

M3 - Article

C2 - 12614212

AN - SCOPUS:0037336639

VL - 120

SP - 793

EP - 800

JO - British Journal of Haematology

JF - British Journal of Haematology

SN - 0007-1048

IS - 5

ER -